PA5-20202

antibody from Invitrogen Antibodies

Targeting: TLR9 CD289

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-20202

Provider

Invitrogen Antibodies

Product name

TLR9 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

A suggested positive control is mouse spleen tissue lysate. PA5-20202 can be used with blocking peptide PEP-0330.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

100 µg

Concentration

1 mg/mL

Storage

Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C

References

Submitted references

Toll-Like Receptor 9 Expression Levels in Breast Carcinoma Correlate with Improved Overall Survival in Patients Treated with Neoadjuvant Chemotherapy and Could Serve as a Prognostic Marker.

Singh A, Bandyopadhyay A, Mukherjee N, Basu A
Genetic testing and molecular biomarkers 2021 Jan;25(1):12-19

---

Influenza-induced immune suppression to methicillin-resistant Staphylococcus aureus is mediated by TLR9.

Martínez-Colón GJ, Warheit-Niemi H, Gurczynski SJ, Taylor QM, Wilke CA, Podsiad AB, Crespo J, Bhan U, Moore BB
PLoS pathogens 2019 Jan;15(1):e1007560

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent analysis of mouse spleen cells using a CD289/TLR9 polyclonal antibody (Product # PA5-20202) at a 10 µg/mL dilution.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence of TLR9 in mouse spleen cells with TLR9 Polyclonal Antibody (Product # PA5-20202) at 10 µg/mL.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig 1 TLR9 overexpression in lung immune cells post-IAV infection. (A) Relative gene expression of TLRs (9, 7, 3, 2, 4) by RTqPCR and (B) western blotting of TLR9 and beta-actin. RNA and protein were isolated from lung leukocytes post-collagenase digestion in mice infected with 100 PFUs of H1N1 (PR8) for 5 days or placebo (PBS). beta-actin was used to normalize RNA in samples. (C) Frequency of TLR9 + cells measured by flow cytometry in lung immune cells post-collagenase digestion. Gating was as follows: CD4 + T cells (CD45 + ,CD90.2 + , CD3 + , CD4 + ), CD8 + T cells (CD45 + ,CD90.2 + , CD3 + , CD4 - , CD8 + ), natural killer cells (CD45 + ,CD90.2 +, NKp46 + ), B cells (CD45 + ,CD90.2 - , CD19 + ), neutrophils (CD45 + , CD11b + , LY6G + ), interstitial macrophages (CD45 + , CD64 + , CD11b + , F4/80 + ), alveolar macrophages (CD45 + , CD64 + , CD11C + , Siglec F + ) and dendritic cells (CD45 + , CD64 - , CD11c + , MCHII high ). Staining for TLR9 was performed on cells which were fixed and permeabilized. (D) Relative expression of TLRs (9, 7, 3, 2, 4) after lung macrophage isolation by adherence selection from PBS or IAV-infected mice. (E) Relative expression of TLRs (9, 7, 3, 2, 4) in alveolar macrophages infected or not ex-vivo with H1N1 (MOI:0.01) for 24 hours. (F) BMDMs from Balb/c mice infected with H1N1 at MOI:0.01 and measured for TLR9 mRNA after 48h. Statistics are student T test between comparative groups. *P